This suggests that the treatment of cancer cells with CDK4/6i induces or inhibits a cellular factor (named in the literature E1A-like activity)23 that not only affects E1A expression (which is mainly responsible for driving viral replication) but could also affect other viral genes, including E2, which is known to be activated by E2F143,47. The gene discussed is CDK4; the disease is cancer.